荣昌生物
(688331)
| 流通市值：190.33亿 | | | 总市值：658.75亿 |
| 流通股本：1.63亿 | | | 总股本：5.64亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 1,121,501,900.46 | 1,197,548,786.32 | 1,070,277,163.56 | 1,273,915,008.95 |
| 交易性金融资产 | 1,623,846,294.92 | 1,215,510,584.77 | 109,343,391.25 | 9,171,261.22 |
| 应收票据及应收账款 | 397,605,098.92 | 659,302,841.63 | 563,769,492.57 | 549,710,992.32 |
| 其中：应收票据 | 132,450,420.48 | 236,528,082.25 | 201,780,450.58 | 194,385,130.59 |
| 应收账款 | 265,154,678.44 | 422,774,759.38 | 361,989,041.99 | 355,325,861.73 |
| 应收款项融资 | 79,061,554.17 | 58,785,548.2 | 66,649,661.83 | 11,880,522.64 |
| 预付款项 | 124,206,797.12 | 91,744,403.64 | 199,387,966.97 | 181,044,440.89 |
| 其他应收款合计 | 50,992,820.56 | 84,025,528.45 | 50,495,704.79 | 28,447,508.3 |
| 存货 | 702,656,118.57 | 661,485,470.81 | 657,583,963.29 | 641,247,289.43 |
| 其他流动资产 | 12,187,397.96 | 13,482,089.6 | 1,635,532.68 | 2,743,063.99 |
| 流动资产合计 | 4,112,057,982.68 | 3,981,885,253.42 | 2,719,142,876.94 | 2,698,160,087.74 |
| 非流动资产: | | | | |
| 长期股权投资 | 13,676,211.31 | 13,769,422.88 | 11,259,100.76 | 8,737,936.81 |
| 其他权益工具投资 | 17,484,664.92 | 115,174,185.71 | 119,152,359.03 | 94,792,886.55 |
| 其他非流动金融资产 | 10,084,227.81 | 10,084,227.81 | 11,537,475.88 | 5,037,475.88 |
| 固定资产 | 2,228,903,917.24 | 2,282,643,651.51 | 2,323,127,608.78 | 2,367,746,020.86 |
| 在建工程 | 678,766,788.57 | 646,823,147.81 | 535,489,814.61 | 406,420,464.56 |
| 使用权资产 | 143,025,506.17 | 36,589,501.09 | 48,418,068.25 | 62,762,795.54 |
| 无形资产 | 150,092,500.82 | 152,484,577.29 | 154,667,578.99 | 153,902,186.39 |
| 长期待摊费用 | 503,481.55 | 665,656.15 | 1,599,492.74 | 2,492,190.55 |
| 其他非流动资产 | 10,598,624.69 | 7,952,665.3 | 52,735,508.14 | 50,306,072.04 |
| 非流动资产合计 | 3,253,135,923.08 | 3,266,187,035.55 | 3,257,987,007.18 | 3,152,198,029.18 |
| 资产总计 | 7,365,193,905.76 | 7,248,072,288.97 | 5,977,129,884.12 | 5,850,358,116.92 |
| 流动负债: | | | | |
| 短期借款 | 1,077,237,499.06 | 1,221,760,613.73 | 1,071,410,580.8 | 1,320,553,083.34 |
| 应付票据及应付账款 | 276,575,922.32 | 285,851,434.78 | 194,761,229.05 | 209,201,828.9 |
| 应付账款 | 276,575,922.32 | 285,851,434.78 | 194,761,229.05 | 209,201,828.9 |
| 合同负债 | 305,136,055.45 | 320,104,130.62 | 571,834,427.34 | 1,265,886.69 |
| 应付职工薪酬 | 209,865,263.16 | 217,483,490.55 | 213,004,511.36 | 195,162,276.35 |
| 应交税费 | 50,214,939.85 | 75,867,789.92 | 48,468,857.92 | 30,074,215.92 |
| 其他应付款合计 | 374,822,073.87 | 399,672,514.63 | 320,588,843.38 | 267,878,981.77 |
| 一年内到期的非流动负债 | 269,344,357.77 | 228,049,052.12 | 390,029,409.55 | 508,021,662.64 |
| 其他流动负债 | 37,335,138.97 | 38,669,467.65 | 22,700,635.28 | 15,736,850.57 |
| 流动负债合计 | 2,600,531,250.45 | 2,787,458,494 | 2,832,798,494.68 | 2,547,894,786.18 |
| 非流动负债: | | | | |
| 长期借款 | 652,416,864.55 | 732,165,601.37 | 696,200,059.51 | 816,730,338.19 |
| 租赁负债 | 95,392,399.59 | 19,733,249.13 | 25,274,131.9 | 29,236,692.56 |
| 递延收益 | 88,388,737.48 | 89,283,592.41 | 92,935,766.23 | 91,966,536.39 |
| 递延所得税负债 | - | 10,609,694.49 | 9,838,368.16 | 7,039,192.51 |
| 非流动负债合计 | 836,198,001.62 | 851,792,137.4 | 824,248,325.8 | 944,972,759.65 |
| 负债合计 | 3,436,729,252.07 | 3,639,250,631.4 | 3,657,046,820.48 | 3,492,867,545.83 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 564,477,483 | 563,710,243 | 563,608,243 | 563,608,243 |
| 资本公积 | 6,965,068,566.64 | 6,923,796,632.13 | 6,923,757,144.6 | 6,960,504,191.9 |
| 减:库存股 | 287,929,643.72 | 237,195,480.77 | 262,382,928.1 | 343,271,955.74 |
| 其他综合收益 | -73,192,563.48 | -34,773,858.14 | -32,327,629.91 | -51,910,054.43 |
| 未分配利润 | -3,239,959,188.75 | -3,606,715,878.65 | -4,872,571,765.95 | -4,771,439,853.64 |
| 归属于母公司股东权益合计 | 3,928,464,653.69 | 3,608,821,657.57 | 2,320,083,063.64 | 2,357,490,571.09 |
| 股东权益合计 | 3,928,464,653.69 | 3,608,821,657.57 | 2,320,083,063.64 | 2,357,490,571.09 |
| 负债和股东权益合计 | 7,365,193,905.76 | 7,248,072,288.97 | 5,977,129,884.12 | 5,850,358,116.92 |
| 公告日期 | 2026-04-29 | 2026-03-28 | 2025-10-31 | 2025-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |